$75M Term Loan Bolsters Alvotech’s Liquidity Amid Growth Push
Event summary
- $75M term loan facility maturing December 31, 2027, led by GoldenTree Asset Management.
- Follows $165M equity raise in June 2026; total new capital access now $240M.
- Funds earmarked for R&D pipeline and global product launches.
- Loan bears 12.5% interest rate, payable monthly in cash.
The big picture
Alvotech’s latest financing move underscores the biosimilar sector’s capital-intensive nature, where liquidity is critical for navigating regulatory hurdles and scaling commercial operations. The $75M term loan complements its recent equity raise, reflecting investor confidence in its pipeline but also the pressure to deliver on high-cost development programs. With 30 biosimilars in development, the company’s ability to execute will determine whether this funding translates into market share gains.
What we're watching
- Debt Management
- How Alvotech will balance the 12.5% interest rate on this loan with its growth ambitions.
- Pipeline Execution
- Whether the $240M in new capital will accelerate FDA approvals for key biosimilar candidates.
- Commercial Expansion
- The pace at which Alvotech can scale its global commercial footprint with this funding.
Related topics